OTC: VRCI about to be the next Medijean
Verde’s website reveals a small line in their description that paints the big picture. “Currently the company is working on a Research and Development initiative in Canada.” https://verdescienceinc.com/about/about-verde-science/ If Verde were to receive an R&D grant from Health Canada, it would put them in a very powerful position over other Canadian players that are all chasing the MMPR license. Right now their only real competitor in R&D would be Medijean. Here’s a quote from an article on Medijean’s R&D license, “MediJean is one of the first companies in Canada to receive a research and development exemption from Health Canada that permits it to grow medical marijuana as part of the new Federal Marijuana for Medical Purposes Regulations (MMPR) program. The company says their commitment to research and development includes growing the knowledge bank that exists for this important medicine. Currently they have their scientists performing research on the over 200 "building block" cannabis strains that hold the most promise for medical marijuana products.” https://www.cemag.us/news/2013/10/biopharm-company-announces-medical-marijuana-r-d R&D is an MMPR exemption that sees companies working with the government to develop the science of MMJ and set standards that MMPR holders will be subject to. The R&D grant is also fully funded by the Canadian government which means guaranteed revenues for VRCI shareholders, if approved. Our DD has revealed that VRCI already has a 40k sq ft. facility in BC, Canada that is under the old MMAR license. They have two PhD scientists on board, which have already submitted the thesis required to qualify for the R&D grant. The CEO of ticker, AMX: INO, a $10.00 stock, acted as an advisor to Verde and their scientists prior to submitting their thesis. The thesis is based on their aeroponic technology which, based on their PR’s and website, Verde believes is the highest quality, yield, purity, and environmentally friendly method of growing. They clearly want to make it an industry standard and R&D seems to be how they plan on setting that standard. If Health Canada determined aeroponics was the best way to develop mite and mildew free MMJ, Verde would corner the market. Finally, VRCI will be a presenter at the 2014 Aegis conference in Las Vegas on September 12th. They are clearly targeting big pharma and big money. https://www.meetmax.com/sched/event_25932/~public/conference_home.html?event_id=25932 We believe there could be news following the Aegis conference. Trading at .01, down from .08 a few months ago and only about 150mm O/S, there’s more than enough reasons to call VRCI a strong buy.